Clinical Evaluation of Hepatic Fibrosis in Chinese Patients with Nonalcoholic Fatty Liver Disease with FibroScan

Zeli Gao^1*, Xiaoli Lin², Guoyu Chen¹, Jieru Ji¹, Mingfeng Tang², Xiaotong He¹, Qinghui Xiong², Ming Li^2*

¹Department of Gastroenterology, People’s Hospital of Pudong New Area, Shanghai, China.
²Laboratory of Innovative Medicine, Hong Kong.

DOI: 10.4236/cm.2015.62013                

Abstract

Aim: The clinical value of FibroScan in evaluation of hepatic fibrosis was assessed in Chinese patients with nonalcoholic fatty liver disease (NAFLD). Methods: Liver stiffness and other NAFLD related variables were measured in NAFLD patients with either elevated or normal hyaluronic acid (HA) levels, and in healthy volunteers respectively. Moreover, hepatic fibrosis rat model was used for the correlation analysis between the measured liver elasticity and its corresponding pathological changes. Results: The severity of NAFLD in patients was positively correlated with both HA level and FibroScan values suggesting that fibrosis occured along with the progression of NAFLD. Interestingly, the FibroScan value was found to change at an earlier stage of the disease than that of HA level. The mean liver elasticity in the sampling volume of the region of interest in experimental rats, which were subject to the induction of liver fibrosis using peritoneal injection of carbon tetrachloride (CCl4) for 6 or 9 weeks respectively, was measured using Fibroscan. The examination of pathological changes of these experimental rats demonstrated the positive correlation of the measured elasticity values with the extent (severity) of the corresponding pathological changes in the rats of 6 weeks post induction of liver fibrosis with a moderate liver fibrosis, or 9 weeks with a severe liver fibrosis. The average liver stiffness for the normal liver (S0) was 4.51 ± 0.82 kPa, for moderate liver fibrosis (S2) was 6.91 ± 1.32 kPa, and for severe liver fibrosis (S3) 9.62 ± 1.82 kPa. Conclusion: FibroScan can be used to objectively and quantitatively identify the trend in the changing stiffness of the liver and noninvasively detect the development of liver fibrosis.

Keywords

FibroScan, Nonalcoholic Fatty Liver Disease, Hyaluronic Acid, Ultrasound Elastography

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Adams, L.A. and Angulo, P. (2006) Treatment of Non-Alcoholic Fatty Liver Disease. Postgraduate Medical Journal, 82, 315-322. http://dx.doi.org/10.1136/pgmj.2005.042200
[2]	Paschos, P. and Paletas, K. (2009) Non Alcoholic Fatty Liver Disease and Metabolic Syndrome. Hippokratia, 13, 9-19.
[3]	Brunt, E.M. (2004) Nonalcohlic Steatohepatitis. Seminars in Liver Disease, 24, 3-20. http://dx.doi.org/10.1055/s-2004-823098
[4]	Wahl, K., Rosber, G., Vaske, B., et al. (2012) Biopsy—Controlledliver Fibrosis Staging Using the Enhanced Liver Fibrosis Score Comparedto Transient Elastography. PLoS ONE, 7, e51906．
[5]	Scott, D.R. and Levy, M.T. (2010) Liver Transient Elastography (Fibroscan®): A Place in the Management Algorithms of Chronic Viral Hepatitis. Antiviral Therapy, 15, 1-11. http://dx.doi.org/10.3851/IMP1474
[6]	Kawamoto, M., Mizuguchi, T., Katsuramaki, T., Nagayama, M., Oshima, H., Kawasaki, H., et al. (2006) Assessment of Liver Fibrosis by a Noninvasive Method of Transient Elastography and Biochemical Markers. World Journal of Gastroenterology, 12, 4325-4330.
[7]	Alisi, A., Pinzani, M. and Nobili, V. (2009) Diagnostic Power of Fibroscan in Predicting Liver Fibrosis in Nonalcoholic Fatty Liver Disease. Hepatology, 50, 2048-2049. http://dx.doi.org/10.1002/hep.23345
[8]	Foucher, J., Castera, L., Bernard, P.H., Adhoute, X., Laharie, D., Bertet, J., et al. (2006) Prevalence and Factors Associated with Failure of Liver Stiffness Measurement Using FibroScan in a Prospective Study of 2114 Examinations. European Journal of Gastroenterology & Hepatology, 18, 411-412. http://dx.doi.org/10.1097/00042737-200604000-00015
[9]	Greenleaf, J.F., Fatemi, M. and Insana, M. (2003) Selected Methods for Imaging Elastic Properties of Biological Tissues. Annual Review of Biomedical Engineering, 5, 57-78. http://dx.doi.org/10.1146/annurev.bioeng.5.040202.121623
[10]	Bercoff, J., Tanter, M. and Fink, M. (2004) Supersonic Shear Imaging: A New Technique for Soft Tissue Elasticity Mapping. IEEE Transactions on Ultrasonics Ferroelectrics and Frequency Control, 51, 396-409.
[11]	Fatty Liver and Alcoholic Liver Disease Group of the Chinese Association of Medicine (2006) The Criteria for the Diagnosis of NAFLD. Chin J Hepatol, 14, 161-163.
[12]	Sandrin, L., Fourquet, B., Hasquenoph, J.M., Yon, S., Fournier, C., Mal, F., et al. (2003) Transient Elastography: A New Noninvasive Method for Assessment of Hepatic Fibrosis. Ultrasound in Medicine & Biology, 29, 1705-1713. http://dx.doi.org/10.1016/j.ultrasmedbio.2003.07.001
[13]	de Ledinghen, V., Wong, V.W. and Vergniol, J. (2012) Diagnosis of Liver Fibrosis and Cirrhosis Using Liver Stiffness Measurement: Comparison between M and XL Prob of Fibroscan. Journal of Hepatology, 56, 833-839. http://dx.doi.org/10.1016/j.jhep.2011.10.017
[14]	Brunt, E.M., Janney, C.G., Di Bisceglie, A.M., Neuschwander-Tetri, B.A. and Bacon, B.R. (1999) Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging the Histological Lesions. The American Journal of Gastroenterology, 94, 2467-2474. http://dx.doi.org/10.1111/j.1572-0241.1999.01377.x
[15]	Burt, A.D., Mutton, A. and Day, C.P. (1998) Diagnosis and Interpretation of Steatosis and Steatohepatitis. Seminars in Diagnostic Pathology, 15, 246-258.
[16]	Knodell, R.G., Ishak, K.G., Black, W.C, et al. (1981) Formulation and Application of a Numerical Scoring System for Assessing Histological Activity in Asymptomatic Chronic Active Hepatitis. Hepatology, 1, 431-435. http://dx.doi.org/10.1002/hep.1840010511
[17]	Sanada, M., Ebara, M., Fukuda, H., Yoshikawa, M., Sugiura, N., Saisho, H., et al. (2000) Clinical Evaluation of Sonoelasticity Measurement in Liver Using Ultrasonic Imaging of Internal Forced Low-Frequency Vibration. Ultrasound in Medicine & Biology, 26, 1455-1460. http://dx.doi.org/10.1016/S0301-5629(00)00307-0
[18]	Kim, K.M., Choi, W.B., Park, S.H., et al. (2007) Diagnosis of Hepatic Steatosis and Fibrosis by Transient Elastography in Asymptomatic Healthy Individuals: A Prospective Study of Living Related Potential Liver Donors. Journal of Gastroenterology, 42, 382-388. http://dx.doi.org/10.1007/s00535-007-2016-1
[19]	Poynard, T., de Ledinghen, V., Zarski, J.P., et al. (2012) Relative Performances of FibroTest, Fibroscan, and Biopsy for the Assessment of the Stage of Liver Fibrosis in Patients with Chronic Hepatitis C: A Step Towardthe Truth in the Absence of a Gold Standard. Journal of Hepatology, l56, 541-548.
[20]	Topil’skaia, N., Morozov, S., Isakov, V., Trufanova, I. and Kaganov, B. (2011) [Elastography Efficiency in the Liver Fibrosis Determination in Patients with Nonalcoholic Fatty Liver Disease]. Eksperimental’naia i Klinicheskaia Gastroenterologiia (Experimental & Clinical Gastroenterology), 26, 26-31.
[21]	Ziol, M., Handra-Luca, A., Kettaneh, A., et al. (2005) Noninvasive Assessment of Liver Fibrosis by Measurement of Stiffness in Patients with Chronic Hepatitis C. Hepatology, 41, 48-54. http://dx.doi.org/10.1002/hep.20506
[22]	Kim, K.M., Choi, W.B., Park, S.H., Yu, E., Lee, S.G., Lim, Y.S., et al. (2007) Diagnosis of Hepatic Steatosis and Fibrosis by Transient Elastography in Asymptomatic Healthy Individuals: A Prospective Study of Living Related Potential Liver Donors. Journal of Gastroenterology, 42, 382-388. http://dx.doi.org/10.1007/s00535-007-2016-1
[23]	Myers, R.P., Pomier-Layrargues, G., Kirsch, R., Pollett, A., Beaton, M., Levstik, M., et al. (2012) Discordance in Fibrosis Staging between Liver Biopsy and Transient Elastography Using the FibroScan XL Probe. Journal of Hepatology, 56, 564-570. http://dx.doi.org/10.1016/j.jhep.2011.10.007
[24]	Wu, J. and Danielsson, A. (1995) Detection of Hepatic Fibrogenesis: A Review of Available Techniques. Scandinavian Journal of Gastroenterology, 30, 817-825. http://dx.doi.org/10.3109/00365529509101585
[25]	Lebensztejn, D.M., Wierzbicka, A., Socha, P., Pronicki, M., Skiba, E., Werpachowska, I., et al. (2011) Cytokeratin-18 and Hyaluronic Acid Levels Predict Liver Fibrosis in Children with Non-Alcoholic Fatty Liver Disease. Acta Biochimica Polonica, 58, 563-566.
[26]	Schaffler, A., Scholmerich, J. and Buchler, C. (2005) Mechanisms of Disease: Adipocytokines and Visceral Adipose Tissue—Emerging Role in Nonalcoholic Fatty Liver Disease. Nature Reviews Gastroenterology and Hepatology, 2, 273-280. http://dx.doi.org/10.1038/ncpgasthep0186
[27]	Harrison, S.A., Kadakia, S., Lang, K.A. and Schenker, S. (2002) Nonalcoholic Steatohepatitis: What We Know in the New Millennium. The American Journal of Gastroenterology, 97, 2714-2724.
[28]	Saadeh, S., Cammell, G., Carey, W.D., Younossi, Z., Barnes, D. and Easley, K. (2001) The Role of Liver Biopsy in Chronic Hepatitis C. Hepatology, 33, 196-200. http://dx.doi.org/10.1053/jhep.2001.20534
[29]	Poynard, T., Ratziu, V. and Bedossa, P. (2000) Appropriateness of Liver Biopsy. Canadian Journal of Gastroenterology, 14, 543-548.
[30]	Schaffler, A., Scholmerich, J. and Buchler, C. (2005) Mechanisms of Disease: Adipocytokines and Visceral Adipose Tissue—Emerging Role in Nonalcoholic Fatty Liver Disease. Nature Reviews Gastroenterology and Hepatology, 2, 273-280. http://dx.doi.org/10.1038/ncpgasthep0186
[31]	Harrison, S.A., Kadakia, S., Lang, K.A. and Schenker S. (2002) Nonalcoholic Steatohepatitis: What We Know in the New Millennium. The American Journal of Gastroenterology, 97, 2714-2724.
[32]	de Ledinghen, V., Wong, V.W., Vergniol, J., Wong, G.L., Foucher, J., Chu, S.H., et al. (2012) Diagnosis of Liver Fibrosis and Cirrhosis Using Liver Stiffness Measurement: Comparison between M and XL Probe of FibroScan®. Journal of Hepatology, 56, 833-839. http://dx.doi.org/10.1016/j.jhep.2011.10.017